Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Lyrica CR Extended-Release Tablets CV

Pfizer news release; 2017 Oct 12

Pfizer Inc. has announced that the US Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN).

Dosage/administration: Lyrica CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed. The initial dose for DPN is 165 mg/day; the maximum dose is 330 mg/day within 1 week. For PHN, the initial dose is 165 mg/day; the maximum dose is 330 mg/day within 1 week, with a maximum dose of 660 mg/day.

Adverse reactions: The most common adverse reactions reported with Lyrica CR were dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain.

Citation:

US FDA approves LYRICA CR (pregabalin) extended-release tablets CV. [news release]. New York, NY: Pfizer Inc. October 12, 2017. http://press.pfizer.com/press-release/us-fda-approves-lyrica-cr-pregabalin-extended-release-tablets-cv. Accessed October 30, 2017.

This Week's Must Reads

PD Global Burden More than Doubles, from 1990-2016, Lancet Neurol; ePub 2018 Oct 1; Dorsey, et al

Disparities Found in Dementia Medication Use for PD, JAMA Neurol, ePub 2018 Oct 1; Mantri, Fullard, et al

Gray Matter Abnormalities in Movement Disorders, Neurology; ePub 2018 Oct 10; Maurer, LaFaver, et al

Periodic Limb Movements in Sleep Increase with Age, Clin Neurophysiol; 2018 Nov; Leary, Moore IV, et al

Cognitive Ability Assessment Tool Proves Effective, Mov Disord; ePub 2018 Oct 10; Holden, Medina, et al

Must Reads in FDA Actions

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3

FDA Approves Epidiolex for Rare Epilepsy Forms, FDA news release: 2018 Jun 25